Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGIMEN-KS HIV
NCT07308886Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2026
- Primary completion
- Jan 2036
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-7 in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Started Apr 2026; status: recruiting.
02
Drugs
recombinant human interleukin-7
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT07308886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308886.